COMPASS Pathways (CMPS) Could Be 49% Below Fair Value Following Its Phase III Progress

COMPASS Pathways (CMPS) is back in focus after recent share price swings, with the mental health biotech drawing attention as investors reassess its psilocybin-based COMP360 pipeline and current valuation. Recent trading tells a mixed story for COMPASS Pathways. The share price fell around 4% over the last day and is down about 10% over the past week, yet the year to date share price return is close to 90% and the 1 year total shareholder return is roughly 116%. That combination suggests...